Compare Electronic Arts Inc. (EA) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Electronic Arts Inc. vs IDEXX Laboratories, Inc. — how do they compare? Electronic Arts Inc. trades at $207.39 (market cap $51.97B), while IDEXX Laboratories, Inc. trades at $574.5 (market cap $43.94B). The key difference: Electronic Arts Inc. is the larger of the two by market cap, and Electronic Arts Inc. pays a 0.37% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals.
| EA | IDXX | |
|---|---|---|
Market Cap | $51.97B | $43.94B |
Sector | Technology | Health |
52-Week High | $207.27 | $766.68 |
52-Week Low | $147.79 | $514.61 |
Enterprise Value | $50.54B | $44.84B |
Dividend Yield | 0.37% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Electronic Arts (EA) trades at $207.31, up 0.32% on the day, with a bullish technical signal from moving averages and strong support at $205. The company reported Q4 2025 EPS beat but Q1 2026 miss, with revenue stable around $7.5B and a net income margin of 11.78%. Recent launches like EA SPORTS College Football 27 and UFC 6 highlight ongoing product momentum, while a potential $55B acquisition by Saudi investors adds strategic intrigue.
Outlook remains mixed: high valuation ratios (P/E 59.05) suggest premium pricing, but robust cash flow and dividend payments support shareholder returns. Key risks include earnings volatility and competitive pressures in gaming. Analyst consensus leans Hold (56.06%), indicating cautious optimism amid execution uncertainties.
IDXX trades at $572.38, up 5.86% over 24 hours, with a neutral technical signal and strong fundamentals. The company reported Q1 2026 EPS of $3.47, beating estimates, and maintains robust profitability with a 24.63% net margin. Revenue growth accelerated to $4.3 billion in 2025, supported by innovation in veterinary diagnostics and AI integration. Cash flow from operations remains healthy at $1.18 billion, though net cash flow was negative $108 million due to financing activities.
Outlook is positive given consistent earnings beats and analyst consensus leaning buy (59% of ratings). Key risks include high valuation multiples (P/E 40.99) and competitive pressures in medical devices. The stock's proximity to its 52-week high suggests momentum but warrants caution on pullbacks. Institutional sentiment is bolstered by product expansions like taeniid tapeworm detection and SDMA integration for kidney disease screening.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Electronic Arts Inc.
EA is one of the world's largest third-party video game publishers and has transitioned from a console-based video game publisher to the one of the largest publishers on consoles, PC, and mobile. The firm owns number of large franchises, including Madden, FIFA, Battlefield, Apex Legends, Mass Effect, Dragon's Age, and Need for Speed.
Read more on EA →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
